Literature DB >> 22554355

Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier.

F Campigotto, D Neuberg, J I Zwicker.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22554355      PMCID： PMC4528617          DOI： 10.1111/j.1538-7836.2012.04766.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  10 in total

1.  High D-dimer levels are associated with poor prognosis in cancer patients.

Authors:  Cihan Ay; Daniela Dunkler; Robert Pirker; Johannes Thaler; Peter Quehenberger; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

2.  Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.

Authors:  Stephen Couban; Michael Goodyear; Margot Burnell; Sean Dolan; Parveen Wasi; David Barnes; Darlene Macleod; Erica Burton; Pantelis Andreou; David R Anderson
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

3.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

4.  Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism.

Authors:  S Parpia; J A Julian; L Thabane; A Y Y Lee; F R Rickles; M N Levine
Journal:  Contemp Clin Trials       Date:  2011-07-18       Impact factor: 2.226

5.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

6.  High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).

Authors:  Cihan Ay; Ralph Simanek; Rainer Vormittag; Daniela Dunkler; Guelay Alguel; Silvia Koder; Gabriela Kornek; Christine Marosi; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

7.  D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.

Authors:  Cihan Ay; Rainer Vormittag; Daniela Dunkler; Ralph Simanek; Alexandru-Laurentiu Chiriac; Johannes Drach; Peter Quehenberger; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

8.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.

Authors:  Guy Meyer; Zora Marjanovic; Judith Valcke; Bernard Lorcerie; Yves Gruel; Philippe Solal-Celigny; Christine Le Maignan; Jean Marc Extra; Paul Cottu; Dominique Farge
Journal:  Arch Intern Med       Date:  2002 Aug 12-26

9.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316

Review 10.  A note on competing risks in survival data analysis.

Authors:  J M Satagopan; L Ben-Porat; M Berwick; M Robson; D Kutler; A D Auerbach
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640
  10 in total
  15 in total

1.  Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.

Authors:  Federico Campigotto; Edie Weller
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 2.  Survival analysis in hematologic malignancies: recommendations for clinicians.

Authors:  Julio Delgado; Arturo Pereira; Neus Villamor; Armando López-Guillermo; Ciril Rozman
Journal:  Haematologica       Date:  2014-09       Impact factor: 9.941

3.  Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need.

Authors:  Gary H Lyman
Journal:  Intern Emerg Med       Date:  2014-05-24       Impact factor: 3.397

4.  Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin.

Authors:  Ariela L Marshall; Federico Campigotto; Donna Neuberg; Betty Rowe; Jean M Connors
Journal:  Clin Appl Thromb Hemost       Date:  2015-04-07       Impact factor: 2.389

5.  Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.

Authors:  Jeffrey I Zwicker; Benjamin L Schlechter; Jack D Stopa; Howard A Liebman; Anita Aggarwal; Maneka Puligandla; Thomas Caughey; Kenneth A Bauer; Nancy Kuemmerle; Ellice Wong; Ted Wun; Marilyn McLaughlin; Manuel Hidalgo; Donna Neuberg; Bruce Furie; Robert Flaumenhaft
Journal:  JCI Insight       Date:  2019-02-21

6.  Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

Authors:  Jessica Donato; Federico Campigotto; Erik J Uhlmann; Erika Coletti; Donna Neuberg; Griffin M Weber; Jeffrey I Zwicker
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

Review 7.  Top ten errors of statistical analysis in observational studies for cancer research.

Authors:  A Carmona-Bayonas; P Jimenez-Fonseca; A Fernández-Somoano; F Álvarez-Manceñido; E Castañón; A Custodio; F A de la Peña; R M Payo; L P Valiente
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

8.  A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Authors:  Çağlar Çağlayan; Jordan S Goldstein; Turgay Ayer; Ashish Rai; Christopher R Flowers
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

9.  Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Authors:  Jeffrey I Zwicker; Howard A Liebman; Kenneth A Bauer; Thomas Caughey; Federico Campigotto; Rachel Rosovsky; Simon Mantha; Craig M Kessler; Jonathan Eneman; Vidya Raghavan; Heinz-Joseph Lenz; Andrea Bullock; Elizabeth Buchbinder; Donna Neuberg; Bruce Furie
Journal:  Br J Haematol       Date:  2012-12-13       Impact factor: 6.998

10.  Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality.

Authors:  C Ay; F Posch; A Kaider; C Zielinski; I Pabinger
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.